Steatotic liver disease was reported in 49% of participants switching to BIC/FTC/TAF versus 29% switching to DTG/3TC.
ViiV Healthcare press release
ViiV Healthcare announced 96-week data from a sub-group analysis of PASO DOBLE (GeSIDA 11720), showing that switching to Dovato (dolutegravir/lamivudine (DTG/3TC)) was associated with a lower proportion of steatotic liver disease (SLD) compared to Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)) in adults living with HIV-1 who are virologically suppressed. Results were presented at CROI 2026.
PASO DOBLE is the largest head-to-head, phase IV randomised clinical trial investigating the 2‑drug regimen DTG/3TC compared with the 3‑drug regimen BIC/FTC/TAF for the treatment of HIV-1 in virologically suppressed adults. This planned sub-analysis at 96 weeks focused on SLD, an increasingly recognised comorbidity linked to metabolic health and weight gain in people living with HIV.
Read the full press release here.
Source : ViiV Healthcare
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.